Biosergen (BIOSGN.ST) Stock Analysis & AI Equity Report
Biosergen (BIOSGN.ST) overview
Biosergen (BIOSGN.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Biosergen reported revenue of SEK 0m and operating profit of SEK -20.7m; the year-end share price was 0.53 SEK and market capitalisation was SEK 127m. Biosergen is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Biosergen's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Biosergen
Biosergen AB is a Swedish clinical-stage biotechnology company focused on developing antifungal medicines for severe and life-threatening fungal infections. Its lead candidate, BSG005, is being developed as a treatment for invasive infections in immunocompromised patients, including those undergoing cancer therapy, transplantation, or living with AIDS. The company is listed on Nasdaq First North Growth Market Stockholm.
Generate the Biosergen report
Biosergen is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Biosergen and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.